Table 1.
Inheritance of the AP HSD3B1Allele Worsens Clinical Outcomes with ADT for Castration, Sensitive Prostate Cancera,b
| 1 AP vs. 0 AP Alleles | 2 AP vs. 0 AP Alleles | |||||
|---|---|---|---|---|---|---|
| Cohort | Outcome | HR (95% CI) | P-Value | HR (95% CI) | P-Value | Reference |
| 118 men treated with ADT for post-prostatectomy BCR | PFS | 1.7 (1.0 – 2.9) | 0.041 | 2.4 (1.1 – 5.3) | 0.029 | [9] |
| Distant MFS | 1.7 (1.0 – 2.8) | 0.074 | 2.7 (1.2 – 6.2) | 0.022 | ||
| OS | 2.0 (1.1 – 3.7) | 0.036 | 3.3 (1.3 – 8.3) | 0.013 | ||
| PCaSpS | 1.7 (0.8 – 3.3) | 0.17 | 3.1 (1.1 – 8.7) | 0.027 | ||
| 137 men treated with ADT for post-prostatectomy BCR | PFS | 1.0 (0.7 – 1.7) | 0.85 | 3.4 (1.6 – 7.0) | 0.0013 | |
| 188 men diagnosed with mCSPC | PFS | 1.1 (0.8 – 1.5) | 0.38 | 2.0 (1.1 – 3.8) | 0.027 | |
| OS | 1.5 (1.0 – 2.1) | 0.036 | 2.5 (1.2 – 5.0) | 0.013 | ||
| 102 men treated with ADT for mCSPC | PFS | 1.04 (0.64 – 1.07) | 0.86 | 2.16 (1.01 – 4.58) | 0.046 | [10] |
| 213 men treated with ADT for BCR after primary RT | TTM | 1.19 (0.74 – 1.92) | 0.48 | 2.01 (1.02–3.97) | 0.045 | [14] |
| 1 or 2 AP vs. 0 AP Alleles | ||||||
| Cohort | Outcome | HR (95% CI) | P Value | Reference | ||
| 104 Japanese men treated with ADT for mCSPC | PFS | 2.34 (1.08 – 4.49) | 0.03 | [11] | ||
| OS | 1.36 (0.52 – 2.92) | 0.50 | ||||
| 44 Spanish men treated with ADT for prostate cancer | PFS | 2.4 (NR)c | .038 | [12] | ||
| 174 Caucasian men treated with ADT or ADT and docetaxel for LV mCSPC | 2-year FF CRPC | 1.89 (1.13 – 3.14) | 0.02 | [13] | ||
| 5-year OS | 1.74 (1.01 – 3.00) | 0.045 | ||||
| 301 Caucasian men treated with ADT or ADT and docetaxel for HV mCSPC | 2-year FF CRPC | 1.10 (0.82 – 1.47) | 0.52 | |||
| 5-year OS | 0.89 (0.65 – 1.22) | 0.48 | ||||
a
Clinical studies reporting hazard ratios for prostate cancer progression, metastasis, or survival in cohorts that underwent HSD3B1 genotyping
b
Abbreviations: ADT, androgen deprivation therapy; AP, adrenal-permissive; BCR, biochemical recurrence; CRPC, castration-resistant prostate cancer; FF, freedom from; HV, high-volume; LV, low-volume; mCSPC, metastatic castration-sensitive prostate cancer; MFS, metastasis-free survival; NR, not reported; OS, overall survival; PCaSpS, prostate-cancer-specific survival; PFS, progression-free survival; RT, radiotherapy; TTM, time to metastasis
c
Median PFS ratio calculated